ClinicalTrials.gg
Active, not recruitingNCT05426733BOLD-EXTUpdated Oct 23, 2026

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

A Phase 3 interventional study of Odevixibat in Biliary Atresia, sponsored by Albireo, an Ipsen Company. Active, not recruiting at 30 sites in 14 countries. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Albireo, an Ipsen Company (part of Ipsen) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Biliary Atresia with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Biliary Atresia · United States.

Planned enrollment
4th of 14
180 · median 53
Started
2022
the only one that year
Phase 3
3 of 22
none open now
Registered
18th of 22
by date
Lead sponsor
2 of 22
Albireo, an Ipsen Company

Among the 22 studies in Biliary Atresia with a site in United States, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 3, and was the 18th registered.

Biliary Atresia

78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.

Browse Biliary Atresia studies →

Open to participants now

8 of the 22 studies in Biliary Atresia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Biliary Atresia with a site in United States, or all of them as a file.
02

Study summary

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia

Read the detailed description

This is a Phase 3, multi-center, open-label extension study to evaluate the long-term efficacy and safety of odevixibat in patients with Biliary Atresia (BA). Patients who completed treatment in the A4250-011 BOLD study and meet eligibility criteria for Study A4250-016 (BOLD-EXT) can participate. The duration of the treatment period is 104 weeks, followed by a 4-week Safety Follow-up Period. Patients who wish to continue receiving odevixibat after 104 weeks can remain on treatment in the optional extension period (OEP).

Up to 180 patients will be enrolled at approximately 70 sites in the North America, Europe, the Middle East and Asia-Pacific.

03

Conditions studied

  • Biliary Atresia

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the 104-week Treatment Period of Study A4250-011
  • Signed by caregiver

Exclusion criteria

Exclusion Criteria:

  • Patients who were not compliant with study drug treatment or procedures in Study A4250-011 as per the investigator's discretion
  • Any conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  • Known to any components of odevixibat
  • Patients who are scheduled for a liver transplant or are likely to require a liver transplant in the immediate future based on the investigator's judgment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Odevixibat (A4250)

    Capsules for oral administration once daily for 104 weeks.

    Drug: Odevixibat

Interventions

  • Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).

    Also known as: A4250

06

What researchers measure

Primary outcomes

  1. Proportion of patients who are alive and have not undergone liver transplant

    Time frame: From baseline to Week 104

Secondary outcomes

  1. Change in aspartate aminotransferase (AST) to platelet ratio index (APRI) score

    The APRI (aspartate aminotransferase to platelet ratio index) score estimates the severity of liver fibrosis. A higher score indicates a greater amount of scarring (fibrosis) in the liver. * A score ≤ 0.5 indicates a low likelihood of fibrosis * A score ≥ 1.5 indicates a higher probability of fibrosis

    Time frame: From baseline to Week 104

  2. Change in Fibrosis-4 (Fib-4) score

    The Fib-4 score provides an estimate of the amount of scarring (fibrosis) in the liver. A higher score indicates a greater amount of scarring in the liver. * A score \< 1.45 indicates a low likelihood of fibrosis * A score \> 3.25 indicates a higher probability of fibrosis

    Time frame: From baseline to Week 104

  3. Change in serum bile acids

    Time frame: From Baseline to Weeks 26, 52, 78, and 104

  4. Change in height

    Time frame: From Baseline to Weeks 26, 52, 78 and 104

  5. Change in weight

    Time frame: From Baseline to Weeks 26, 52, 78 and 104

  6. Change in mid-arm circumference

    Measure of growth

    Time frame: From Baseline to Weeks 26, 52, 78 and 104

  7. Time to onset of any sentinel events

    Time frame: From Baseline to Week 104

  8. Change in pediatric end-stage liver disease (PELD) score

    The PELD (pediatric end-stage liver disease) score is a measure of disease severity. PELD scores can range from a negative value (such as -10) to high numbers (such as 45). A higher score indicates more severe disease.

    Time frame: From Baseline to Weeks 26, 52, 78 and 104

07

Study locations

30 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Oct 2026, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 22, 2022
StartActual
Jul 5, 2022
Primary completionEst.
Oct 28, 2026
CompletionEst.
Oct 28, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05426733
Responsible party
Sponsor
First posted
Jun 22, 2022
Start date
Jul 5, 2022
Primary completion
Oct 28, 2026 (estimated)
Completion
Oct 28, 2026 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Odevixibat

Start the discussion